Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.

@article{Dodd2013PrenatalAO,
  title={Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.},
  author={Jodie M. Dodd and Leanne V Jones and Vicki J. Flenady and Rob Cincotta and Caroline A. Crowther},
  journal={The Cochrane database of systematic reviews},
  year={2013},
  volume={7},
  pages={
          CD004947
        }
}
BACKGROUND Preterm birth is a major complication of pregnancy associated with perinatal mortality and morbidity. [...] Key MethodWe searched the Cochrane Pregnancy and Childbirth Group's Trials Register (14 January 2013) and reviewed the reference list of all articles. SELECTION CRITERIA Randomised controlled trials, in which progesterone was given for preventing preterm birth. Expand

Paper Mentions

Interventional Clinical Trial
DESIGN: Observational prospective study. INCLUSION CRITERIA: All women are 18 years old of age or older with high risk for preterm birth, based on clinical history, and between 18.0… Expand
ConditionsPreterm Birth
InterventionDevice
Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.
TLDR
The incidence of perinatal death in the progesterone group was higher, although there was considerable uncertainty around the effect estimate and high heterogeneity between studies, and the CIs crossed the line of no effect. Expand
Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.
TLDR
Although the incidence of perinatal death in the progesterone group was higher, there was considerable uncertainty around the effect estimate and high heterogeneity between studies, and there were no clear group differences found in any of the other maternal or infant outcomes. Expand
Progesterone for the Prevention of Preterm Birth
TLDR
Vaginal progesterone has been found to reduce preterm birth in women with a foreshortened cervix as measured by transvaginal ultrasonography, but there is unfortunately no evidence whatsoever that progester one reduces pre term birth among women with multiple gestations. Expand
Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial
TLDR
Vaginal progesterone was not associated with reduced risk of preterm birth or composite neonatal adverse outcomes, and had no long-term benefit or harm on outcomes in children at 2 years of age. Expand
Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis.
TLDR
Oral progesterone appears to be effective for the prevention of recurrent preterm birth and a reduction in perinatal morbidity and mortality rates in asymptomatic singleton pregnancies with previous spontaneous pre term birth. Expand
Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy.
TLDR
The quality of evidence is low for the primary outcomes and the effectiveness of prophylactic oral betamimetics for the prevention of preterm labour and birth for women with twin pregnancies is unproven. Expand
Neonatal outcome in women receiving vaginal progesterone for prevention of preterm birth
TLDR
There is some evidence that vaginal administration of progesterone in high-risk women for PTB starting in the second trimester and continued till 34 weeks can lower the PTB and improve the neonatal prognosis, without causing any adverse effect to the neonate. Expand
Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM).
TLDR
In this study, progesterone had no significant beneficial or harmful effects on the primary obstetric, neonatal or childhood outcomes. Expand
Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial
TLDR
The results do not support the use of vaginal progesterone pessaries in women with a history of previous spontaneous preterm birth to reduce the risk and severity of respiratory distress syndrome in their infants. Expand
ROLE OF VAGINAL PROGESTERONE IN THE PREVENTION OF PRETERM DELIVERY
TLDR
It is concluded that vaginal pessary containing 100mg natural progesterone daily resulted in significant reduction of the Preterm delivery rate in women with a prior history of one spontaneous Preterm birth. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 171 REFERENCES
Prenatal administration of progesterone for preventing preterm birth.
TLDR
Intramuscular progesterone is associated with a reduction in the risk of preterm birth less than 37 weeks' gestation, and infant birthweight less than 2500 grams. Expand
Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial
TLDR
This trial will provide evidence as to whether or not 17OHPC-treatment is an effective means of preventing bad neonatal outcome due to preterm birth in multiple pregnancies. Expand
Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis
TLDR
Progesterone, administered vaginally, does not prevent preterm birth in women with twin pregnancy and a meta-analysis of published and unpublished data confirmed that progesterone Does not prevent early pretermBirth in womenWith twin pregnancy. Expand
Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial
TLDR
Prophylactic vaginal progesterone reduced the rate of preterm labor and preterm delivery in high-risk pregnancies and there was no significant difference in neonatal death between placebo and progester one groups. Expand
Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study
TLDR
This study will provide evidence for the usefulness and cost-effectiveness of screening for short cervical length at the 18-22 weeks and subsequent progesterone treatment among low risk women. Expand
Trial protocol OPPTIMUM– Does progesterone prophylaxis for the prevention of preterm labour improve outcome?
TLDR
The OPPTIMUM study is a double blind randomized placebo controlled trial to determine whether progesterone prophylaxis to prevent preterm birth has long term neonatal or infant benefit. Expand
Progesterone and the risk of preterm birth among women with a short cervix.
TLDR
In women with a short cervix, treatment with progesterone reduces the rate of spontaneous early preterm delivery and is associated with a nonsignificant reduction in neonatal morbidity. Expand
Study of progesterone for the prevention of preterm birth in twins (STOPPIT): Findings from a trial-based cost-effectiveness analysis
TLDR
There is little economic justification for conducting further research into the use of vaginal progesterone gel in twin pregnancies for the prevention of preterm birth, given the scale of the clinical and economic burden of this condition. Expand
Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
TLDR
17-OHP caproate therapy given to prevent recurrent PTB is associated with a prolongation of pregnancy overall, and especially for women with a previous spontaneous PTB at <34 weeks. Expand
Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trials
TLDR
Combining individual patient data from different randomized trials has potential to provide valuable, clinically useful information regarding the benefits and potential harms of progestogens in women with twin pregnancy overall and in relevant subgroups. Expand
...
1
2
3
4
5
...